TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35644960

Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 1% tetracaine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 92
Study: 33541362

Group type: EXPERIMENTAL
Intervention: PROMIS depression scales
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ) scales
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: SF-36 Mental Health scale
Number of subjects: 651
Study: 35277087

Group type: EXPERIMENTAL
Intervention: E5 group (0.25 mg/kg i.v. loading dose of esmolol, followed by 5 µg/kg/min infusion)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: E10 group (0.5 mg/kg i.v. loading dose of esmolol, followed by 10 µg/kg/min infusion)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: E5 group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: E10 group
Number of subjects: 33
Study: 34946280

Group type: EXPERIMENTAL
Intervention: Dentapen® syringe
Number of subjects: 178

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 178
Study: 36314199

Group type: EXPERIMENTAL
Intervention: BetterBrains intervention
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1510
Study: 32751812

Group type: EXPERIMENTAL
Intervention: Teaching Games for Understanding (TGfU) intervention for six months
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (traditional methodologies)
Number of subjects: 188
Study: 36494306

Group type: EXPERIMENTAL
Intervention: Burst spinal cord stimulation (SCS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-frequency 10,000 Hz spinal cord stimulation (SCS)
Number of subjects: 25
Study: 34474441

Group type: EXPERIMENTAL
Intervention: Ketamine by intravenous continuous infusion (0.25 mg/kg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketamine by intravenous bolus (0.25 mg/kg every hour)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ketamine by intravenous bolus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ketamine by intravenous continuous infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 35639525

Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg BID on day 1, 800 mg BID on days 2-5)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study: 35983527

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) prediction model
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Independent influencing factors of NAFLD
Number of subjects: 200
Study: 36480360

Group type: EXPERIMENTAL
Intervention: Increased gesture exposure through parent-directed training
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (standard exposure to gestures)
Number of subjects: 81
Study: 33893522

Group type: EXPERIMENTAL
Intervention: Cell therapy (mesenchymal stem cells)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Core decompression alone
Number of subjects: 51

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 51
Study: 33231007

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 80
Study: 34228877

Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen (0.3 ml injection)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intralesional vitamin D3 (0.6 ml, 60,000 IU injection)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (0.3 ml injection)
Number of subjects: 80
Study: 32629685

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 284

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 284
Study: 35174790

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal (TEP) hernia repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lichtenstein hernia repair (LHR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both TEP and LHR
Number of subjects: 60
Study: 32481563

Group type: EXPERIMENTAL
Intervention: 75 mg red Korean ginseng extract per day for seven days
Number of subjects: 24
Study: 36196711

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSS) infusion plus standard diuretics therapy (SDT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Etilefrine tablets plus standard diuretics therapy (SDT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of HSS infusion and etilefrine tablets plus standard diuretics therapy (SDT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard diuretics therapy (SDT) alone
Number of subjects: 90
Study: 34336625

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard anesthesia)
Number of subjects: 50
Study: 35719234

Group type: EXPERIMENTAL
Intervention: Intense warm-up after foam rolling (FR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Foam rolling without intense warm-up
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intense warm-up before foam rolling (FR)
Number of subjects: 27
Study: 33887443

Group type: EXPERIMENTAL
Intervention: Remote assessment strategies for physical function and physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person assessments
Number of subjects: 0
Study: 32305727

Group type: EXPERIMENTAL
Intervention: FOLFIRI/bevacizumab
Number of subjects: 773

Group type: COMPARATOR
Intervention: FOLFIRI/cetuximab
Number of subjects: 773
Study: 34224871

Group type: EXPERIMENTAL
Intervention: Laparoscopic urethrolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal approach
Number of subjects: 0
Study: 36066846

Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no Buzzy device)
Number of subjects: 60
Study: 33632072

Group type: EXPERIMENTAL
Intervention: Acute stress (emotionally stressful video)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (non-stressful video)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Higher baseline oxytocin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Naturalistic stress effects
Number of subjects: 37
Study: 32006006

Group type: EXPERIMENTAL
Intervention: D46/NS2/N/ΔM2‐2‐HindIII (vaccine)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34866258

Group type: EXPERIMENTAL
Intervention: Oral dextrose as first line treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Re-checking blood glucose concentrations after oral dextrose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diagnostic threshold for hypoglycaemia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glucose oxidase method of testing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Referral to paediatric services or neonatal intensive care unit
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Administration of intravenous dextrose
Number of subjects: 18
Study: 36457177

Group type: EXPERIMENTAL
Intervention: Functional training group (aerobic and resistance training combined with functional exercises)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional training group (CTG) (resistance and aerobic exercise)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care group (respiratory physiotherapy)
Number of subjects: 76
Study: 34088224

Group type: EXPERIMENTAL
Intervention: Laser acupuncture with 10 mW at LI4 bilaterally (AG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: 30% oral glucose solution (GG)
Number of subjects: 96
Study: 32865148

Group type: EXPERIMENTAL
Intervention: PST-Hospice (Brief Problem-Solving Therapy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: UC + CE (Usual Care plus Caregiver Education)
Number of subjects: 37
Study: 36401749

Group type: EXPERIMENTAL
Intervention: Add-on Celecoxib 400 mg/day
Number of subjects: 109

Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 109
Study: 33535776

Group type: EXPERIMENTAL
Intervention: 90-day risk-standardized mortality rates following isolated CABG surgery
Number of subjects: 137819

Group type: COMPARATOR
Intervention: Society of Thoracic Surgeons composite star ratings
Number of subjects: 137819
Study: 34363315

Group type: EXPERIMENTAL
Intervention: Three-dimensional printed anatomical models (3DP)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Plastinated human specimens
Number of subjects: 63
Study: 34673326

Group type: EXPERIMENTAL
Intervention: TCT (Targeted Cognitive Training)
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 52
Study: 34047921

Group type: EXPERIMENTAL
Intervention: Usual care plus study interventions (N = 3490)
Number of subjects: 4653

Group type: COMPARATOR
Intervention: Usual care (N = 1163)
Number of subjects: 4653
Study: 33478570

Group type: EXPERIMENTAL
Intervention: Silver needle therapy (SNT) and physiotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (physiotherapy alone)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Silver needle therapy (SNT)
Number of subjects: 100
Study: 33070152

Group type: EXPERIMENTAL
Intervention: Fenofibrate 10 mg/kg/day for 1 day or 2 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 32462483

Group type: EXPERIMENTAL
Intervention: Minimally invasive surfactant therapy (MIST)
Number of subjects: 58

Group type: COMPARATOR
Intervention: InSurE (intubate surfactant extubate)
Number of subjects: 58
Study: 36881665

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FFP2 respirator
Number of subjects: 8

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 8
Study: 34618982

Group type: EXPERIMENTAL
Intervention: Omega-3 free carboxylic acids (OM-3CA) 4 g per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 0
Study: 35749440

Group type: EXPERIMENTAL
Intervention: Telehealth behaviour intervention (3 times per week for 12 weeks, including home-based exercise twice a week and individual lifestyle program once a week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General health recommendations and advice for unsupervised walking training (Control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Telehealth behaviour intervention
Number of subjects: 60
Study: 32950502

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35292919

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days.
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Vehicle (control), applied twice daily for 28 days.
Number of subjects: 1313
Study: 37830397

Group type: EXPERIMENTAL
Intervention: Long-pulsed 1,064-nm gallium arsenide (GaAs) laser surgical device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Short-pulsed Nd:YAG laser surgical device
Number of subjects: 20
Study: 32564459

Group type: EXPERIMENTAL
Intervention: Multiple-layer closure (SIMULAC-I)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Single superficial-layer closure (SIMULAC-II)
Number of subjects: 225
Study: 32476162

Group type: EXPERIMENTAL
Intervention: Eflapegrastim 13.2 mg (3.6 mg G-CSF)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Pegfilgrastim 6 mg G-CSF
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Number of subjects: 406
Study: 33958268

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day for 14 weeks
Number of subjects: 84
Study: 35195692

Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine/dolutegravir
Number of subjects: 37

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine/darunavir/cobicistat
Number of subjects: 37
Study: 36396460

Group type: EXPERIMENTAL
Intervention: Guided Participation (GP) intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 34
Study: 35594631

Group type: EXPERIMENTAL
Intervention: Concentrated fish oil (FO) 3 g/d
Number of subjects: 61

Group type: COMPARATOR
Intervention: Corn oil (CO) 3 g/d
Number of subjects: 61
Study: 33293689

Group type: EXPERIMENTAL
Intervention: NIV with helmet
Number of subjects: 59
Study: 35229616

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 1 month (with aspirin for the first month)
Number of subjects: 15968

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy for 1 year followed by aspirin alone
Number of subjects: 15968

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 15968

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy
Number of subjects: 15968
Study: 32688047

Group type: EXPERIMENTAL
Intervention: Power posing (holding powerful postures)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Neutral postures (control group)
Number of subjects: 150
Study: 35481945

Group type: EXPERIMENTAL
Intervention: Electric Muscle Stimulation (EMS) warm-up
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control warm-up
Number of subjects: 12
Study: 33762196

Group type: EXPERIMENTAL
Intervention: Ketamine (Group-K, n=52): 1mg/kg ketamine in 20mL saline
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline (Group-S, n=50): 20mL saline
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline (Group-S, n=50)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ketamine (Group-K, n=52)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ketamine (Group-K, n=52) and Saline (Group-S, n=50)
Number of subjects: 102
Study: 32341582

Group type: EXPERIMENTAL
Intervention: ChemoCalc software
Number of subjects: 20
Study: 34699270

Group type: EXPERIMENTAL
Intervention: Pop-up book about anesthesia
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 148
Study: 33961944

Group type: EXPERIMENTAL
Intervention: Radiomic models (R-model, C-model, E-model, Integ-model) derived from coronary computed tomography angiography (CCTA)
Number of subjects: 161
Study: 32675261

Group type: EXPERIMENTAL
Intervention: Comprehensive opioid reduction protocol
Number of subjects: 186

Group type: COMPARATOR
Intervention: Crossover intervention applied to original control group
Number of subjects: 186
Study: 35240925

Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 20000
Study: 32867541

Group type: EXPERIMENTAL
Intervention: Impersonal educative news articles featuring interviews with suicide prevention experts (two versions: one emphasizing prevention, the other emphasizing prevalence)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Control group (article unrelated to suicide)
Number of subjects: 425
Study: 34187937

Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block (SSNB) with 10ml of 0.5% Bupivacaine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Intra-articular Corticosteroid Injection (IACI) with 40mg Triamcinolone and 1ml 2% Lignocaine
Number of subjects: 86
Study: 32402160

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus Bevacizumab
Number of subjects: 501

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 501
Study: 33284237

Group type: EXPERIMENTAL
Intervention: nal‐IRI 50 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: nal‐IRI 70 mg/m2 every 2 weeks + TMZ 50 mg/m2/d
Number of subjects: 12
Study: 32355285

Group type: EXPERIMENTAL
Intervention: Refined algorithm for OCT-based drusen quantification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Replicated algorithm for OCT-based drusen quantification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous algorithm results
Number of subjects: 0
Study: 33926519

Group type: EXPERIMENTAL
Intervention: Probiotics for 4 weeks
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 2000
Study: 32085778

Group type: EXPERIMENTAL
Intervention: Open-abdomen (OA) approach with active negative pressure peritoneal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fascial closure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life measurement using Euroqol EQ-5D-5L and SF-36 surveys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-utility analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markov modeling for cost per quality-adjusted life years gained
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness acceptability curve using Monte Carlo simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for patients with and without septic shock and APACHE II scores
Number of subjects: 0
Study: 36474797

Group type: EXPERIMENTAL
Intervention: 12-week individualised exercise program combined with behavioural counselling delivered by accredited exercise physiologists
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 12-week individualised exercise program combined with behavioural counselling
Number of subjects: 63
Study: 34663672

Group type: EXPERIMENTAL
Intervention: Daily mobile phone instructional text messages to perform regular outdoor walking and functional leg exercises (n=40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard care (n=39)
Number of subjects: 79
Study: 35499216

Group type: EXPERIMENTAL
Intervention: Telitacicept (80 or 160 mg per week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Telitacicept
Number of subjects: 15
Study: 34222473

Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Citrus aurantium aromatherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 150
Study: 33186125

Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy (performed 3 to 4 times weekly at home with 1 in-office session weekly for the first month)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy
Number of subjects: 8
Study: 33947194

Group type: EXPERIMENTAL
Intervention: Intermittent suction (IS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continuous suction (CS)
Number of subjects: 33
Study: 33863679

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Prediabetes (Pre-DM)
Number of subjects: 2123

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 2123
Study: 36325594

Group type: EXPERIMENTAL
Intervention: B/myeloid MPALisoMPO
Number of subjects: 13

Group type: COMPARATOR
Intervention: Other MPAL subtypes
Number of subjects: 13

Group type: COMPARATOR
Intervention: B-ALL
Number of subjects: 13
Study: 34496755

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 4 mg with 0.5% ropivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dexamethasone
Number of subjects: 0
Study: 33813533

Group type: EXPERIMENTAL
Intervention: 16-week multimodal exercise program (MEP) combining physical and cognitive tasks
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 319
Study: 34343532

Group type: EXPERIMENTAL
Intervention: Early recurrence during the early phase (ER1 group, 0-30 days)
Number of subjects: 2038

Group type: EXPERIMENTAL
Intervention: Early recurrence during the late phase (ER2 group, 31-90 days)
Number of subjects: 2038

Group type: COMPARATOR
Intervention: Patients without early recurrences
Number of subjects: 2038

Group type: EXPERIMENTAL
Intervention: Patients with non-paroxysmal atrial fibrillation in the ER2 group
Number of subjects: 2038
Study: 36159553

Group type: EXPERIMENTAL
Intervention: Qigong (QG) rehabilitation therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine cardiologic medication (Control)
Number of subjects: 68
Study: 33287570

Group type: EXPERIMENTAL
Intervention: Curcuma longa and Boswellia serrata extracts (two tablets twice a day for 1 month)
Number of subjects: 670
Study: 35548913

Group type: EXPERIMENTAL
Intervention: tiapride, 100 mg twice daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: topiramate, 25 mg twice daily
Number of subjects: 56
Study: 33148343

Group type: EXPERIMENTAL
Intervention: Implementation of evidence-based protocols for stroke management in the ED, including triage, administration of tissue plasminogen activator, management of fever, hyperglycaemia, and swallowing, and transfer to a stroke unit.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with ED and stroke clinicians regarding protocol uptake.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Implementation strategy for stroke management protocols.
Number of subjects: 28
Study: 34241768

Group type: EXPERIMENTAL
Intervention: FCPs delivering vocational advice
Number of subjects: 15
Study: 32340616

Group type: EXPERIMENTAL
Intervention: Automated digital reminders + personalized prescribed treatment plan (pPTP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: SimpleMed+ pillboxes (control group)
Number of subjects: 19
Study: 33899302

Group type: EXPERIMENTAL
Intervention: Activity tracker with feedback
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (usual encouragement for ambulation)
Number of subjects: 73
Study: 35978604

Group type: EXPERIMENTAL
Intervention: TACE plus sorafenib
Number of subjects: 156

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 156
Study: 34112266

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stromal cells (UC-MSCs)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care based on intensive insulin therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Allogeneic UC-MSCs
Number of subjects: 53
Study: 35421015

Group type: EXPERIMENTAL
Intervention: Facebook advertising
Number of subjects: 0

Group type: COMPARATOR
Intervention: Google Ads advertising
Number of subjects: 0
Study: 32949255

Group type: EXPERIMENTAL
Intervention: Continuous IV butylscopolamine 100 mg/24 h
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 128